Search Results - "Giovanakis, Marta"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
  2. 2

    First report of plasmid-mediated fluoroquinolone efflux pump QepA in Escherichia coli clinical isolate ST68, in South America by Rincón, Giovanna, Radice, Marcela, Giovanakis, Marta, Di Conza, Jose A, Gutkind, Gabriel

    “…Abstract This is the first report of the presence of qepA1 efflux pump gene in Escherichia coli clinical isolate from Argentina, which was associated to other…”
    Get full text
    Journal Article
  3. 3

    Plasmid-Encoded AmpC (pAmpC) in Enterobacteriaceae: epidemiology of microorganisms and resistance markers by Cejas, Daniela, Fernández Canigia, Liliana, Quinteros, Mirta, Giovanakis, Marta, Vay, Carlos, Lascialandare, Silvana, Mutti, Daniel, Pagniez, Gastón, Almuzara, Marisa, Gutkind, Gabriel, Radice, Marcela

    Published in Revista argentina de microbiología (01-07-2012)
    “…CMY-2 Β-lactamase is an important cause of Β-lactam resistance in Enterobacteriaceae and constitutes the most widespread pAmpC. Although CMY-2 has been…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7

    Evaluation of direct susceptibility testing from blood culture bottles. Clinical usefulness by Soloaga, Rolando N, Carrion, Natalia A, Margari, Alejandra M, Giovanakis, Marta, Sujemecki, Alicia, Efron, Ernesto, Pidone, Juan C, Guelfand, Liliana I, Mendez Aranibar, Mariela

    Published in Revista argentina de microbiología (01-07-2012)
    “…A prospective observational study was conducted in two hospitals of Buenos Aires city (Argentina); 191 clinically significant monomicrobial gram-negative…”
    Get full text
    Journal Article
  8. 8

    Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina by Fernández Canigia, Liliana, Kaufman, Sara, Lanata, Liliana, Vay, Carlos, Giovanakis, Marta, Bantar, Carlos

    Published in Chemotherapy (Basel) (01-01-2009)
    “…Tigecycline is a new antibiotic currently used in healthcare environments where multidrug resistance is prominent. Because there is a constant potential for…”
    Get more information
    Journal Article
  9. 9
  10. 10
  11. 11